Cisplatin followed by olaparib, larotrectinib or entrectinib, and pembrolizumab are recommended for BRCA1/2- or PALB2-mutated cancers, NTRK gene-fusion-positive cancers, and MSI-H/dMMR cancers respectively. The gene discussed is PALB2; the disease is cancer.